9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors

ACCESSWIRE2021-10-04

RALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

JiaocyTi
2021-10-04
JiaocyTi
Good
- JiaocyTi:
  Effort
WjsdSGTi
2021-10-04
WjsdSGTi
Good
- WjsdSGTi:
  Try
Shadowrider
2021-10-04
Shadowrider
Pls like
PanaCota
2021-10-04
PanaCota
Ok

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2172954519?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-04 20:38","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2172954519","market":"us","top_or_hot":-1,"title":"9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors","media":"ACCESSWIRE","content":"<div>\n<p>RALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by ...</p>\n\n<a href=\"https://finance.yahoo.com/news/9-meters-biopharma-inc-appoints-113000014.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 20:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/9-meters-biopharma-inc-appoints-113000014.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>RALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by ...</p>\n\n<a href=\"https://finance.yahoo.com/news/9-meters-biopharma-inc-appoints-113000014.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OLPX","symbol_name":"Olaplex Holdings, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/9-meters-biopharma-inc-appoints-113000014.html","article_id":"2172954519","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2172954519","pubTimestamp":1633351080,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"RALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stag","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OLPX":"Olaplex Holdings, Inc.","HCTI":"Healthcare Triangle, Inc.","TERN":"Terns Pharmaceuticals, Inc.","FWRG":"First Watch Restaurant Group, Inc.","CRCT":"Cricut, Inc."},"translate_title":"9米生物制药公司任命萨曼莎·文蒂米利亚为董事会成员","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALVU":0.9,"CRCT":0.9,"FWRG":0.9,"HCTI":0.9,"INNTW":0.9,"NMTR":0.9,"OLPX":0.9,"TERN":0.9},"content_text":"RALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Samantha Ventimiglia to its Board of Directors.\nMs. Ventimiglia currently serves as Senior Vice President, U.S. Public Affairs at Vertex Pharmaceuticals, Inc., where she is responsible for developing and overseeing the company's policy, government affairs and patient advocacy strategy, including building relationships with state and federal government officials, industry organizations, patient groups and other stakeholders. Previously, Samantha held a similar role as a government affairs director at Astellas Pharma US after a tenure as a principal consultant at Jeffrey J. Kimbell & Associates, a federal government affairs firm representing clients in the healthcare community who are seeking legislative and regulatory solutions to problems related to product approval, coverage and reimbursement and marketing practices. Prior to that, Ms. Ventimiglia was a policy director at the Pharmaceutical Research & Manufacturers of America (PhRMA) and the National Governors Association (NGA) where she played a pivotal role in developing the associations' policy and legislative agenda on Medicare, Medicaid, private sector health care and FDA issues.\n\"We are thrilled to add Samantha's wealth of expertise to our Board of Directors to foster the Company's growth as we continue progressing our product pipeline toward commercialization,\" said Dr. Mark Sirgo, Chairman of 9 Meters. \"Samantha is a seasoned professional in the government healthcare policy and public affairs areas of our industry where her leadership and advisory skills will help us navigate the challenges these areas may present to our business going forward. Her input will be especially helpful as we begin our work with patients, caregivers and advocacy groups involving our products for the treatment of celiac disease and short bowel syndrome\"\nMs. Ventimiglia added, \"I am excited to be joining 9 Meters at this important time as they begin the steps of moving from a clinical to commercial stage company. It is exciting to be involved with one of the leaders in GI drug development whose work in serving people with serious GI diseases is the top priority. I look forward to advising on corporate strategy decisions and political and external relationships as the company moves their products through the regulatory process to market.\"\nAbout 9 Meters Biopharma\n9 Meters Biopharma, Inc. is a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology. The Company is advancing vurolenatide, a proprietary Phase 2 long-acting GLP-1 agonist, for short bowel syndrome (SBS); larazotide, a Phase 3 tight junction regulator in non-responsive celiac disease; and several other early-stage assets. For more information, please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":820311370,"gmtCreate":1633352704582,"gmtModify":1633352817304,"author":{"id":"3581742924827239","authorId":"3581742924827239","name":"JiaocyTi","avatar":"https://static.tigerbbs.com/c16d760078e396b46033bc97afede0c8","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3581742924827239","idStr":"3581742924827239"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820311370","repostId":2172954519,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6089337,"gmtCreate":1633352712849,"gmtModify":1634722234123,"authorId":3581742924827239,"author":{"id":3581742924827239,"idStr":"3581742924827239","authorId":3581742924827239,"name":"JiaocyTi","avatar":"https://static.tigerbbs.com/c16d760078e396b46033bc97afede0c8","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820311370,"type":1,"supId":0,"prevId":0,"content":"<u>Effort</u>","text":"<u>Effort</u>","html":"<u>Effort</u>"}],"langContent":"CN"},{"id":820319018,"gmtCreate":1633352565342,"gmtModify":1633352717394,"author":{"id":"3576295596635298","authorId":"3576295596635298","name":"WjsdSGTi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3576295596635298","idStr":"3576295596635298"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820319018","repostId":2172954519,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6089324,"gmtCreate":1633352571505,"gmtModify":1634722235206,"authorId":3576295596635298,"author":{"id":3576295596635298,"idStr":"3576295596635298","authorId":3576295596635298,"name":"WjsdSGTi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820319018,"type":1,"supId":0,"prevId":0,"content":"Try","text":"Try","html":"Try"}],"langContent":"CN"},{"id":820335357,"gmtCreate":1633352164488,"gmtModify":1633352164917,"author":{"id":"3582060513966213","authorId":"3582060513966213","name":"Shadowrider","avatar":"https://static.tigerbbs.com/5a097dc665f46a3e5b535d2fd63e682b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3582060513966213","idStr":"3582060513966213"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820335357","repostId":2172954519,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820332092,"gmtCreate":1633352028089,"gmtModify":1633352028788,"author":{"id":"3581588474178431","authorId":"3581588474178431","name":"PanaCota","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581588474178431","idStr":"3581588474178431"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820332092","repostId":2172954519,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":28,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2172954519"}